138 related articles for article (PubMed ID: 22052673)
1. A discriminating dissolution method for glimepiride polymorphs.
Bonfilio R; Pires SA; Ferreira LM; de Almeida AE; Doriguetto AC; de Araújo MB; Salgado HR
J Pharm Sci; 2012 Feb; 101(2):794-804. PubMed ID: 22052673
[TBL] [Abstract][Full Text] [Related]
2. Determination of the interaction between glimepiride and hyperbranched polymers in solid dispersions.
Pahovnik D; Reven S; Grdadolnik J; Borštnar R; Mavri J; Zagar E
J Pharm Sci; 2011 Nov; 100(11):4700-9. PubMed ID: 21656768
[TBL] [Abstract][Full Text] [Related]
3. Quantitative determination of two polymorphic forms of imatinib mesylate in a drug substance and tablet formulation by X-ray powder diffraction, differential scanning calorimetry and attenuated total reflectance Fourier transform infrared spectroscopy.
Bellur Atici E; Karlığa B
J Pharm Biomed Anal; 2015 Oct; 114():330-40. PubMed ID: 26099262
[TBL] [Abstract][Full Text] [Related]
4. Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences.
Swanepoel E; Liebenberg W; Devarakonda B; de Villiers MM
Pharmazie; 2003 Feb; 58(2):117-21. PubMed ID: 12641328
[TBL] [Abstract][Full Text] [Related]
5. Study of glimepiride-b-cyclodextrin complex.
Moyano JR; Ventriglia T; Ginés JM; Muñoz F; Rabasco AM
Boll Chim Farm; 2003 Nov; 142(9):390-5. PubMed ID: 14971307
[TBL] [Abstract][Full Text] [Related]
6. Highly Soluble Glimepiride and Irbesartan Co-amorphous Formulation with Potential Application in Combination Therapy.
Cruz-Angeles J; Videa M; Martínez LM
AAPS PharmSciTech; 2019 Mar; 20(4):144. PubMed ID: 30887140
[TBL] [Abstract][Full Text] [Related]
7. Hyperbranched poly(esteramides) as solubility enhancers for poorly water-soluble drug glimepiride.
Reven S; Grdadolnik J; Kristl J; Zagar E
Int J Pharm; 2010 Aug; 396(1-2):119-26. PubMed ID: 20600725
[TBL] [Abstract][Full Text] [Related]
8. A simple and convenient method for the simultaneous in vitro study of metformin and glimepiride tablets.
Ahmed R
Pak J Pharm Sci; 2014 Nov; 27(6):1939-43. PubMed ID: 25362617
[TBL] [Abstract][Full Text] [Related]
9. Solid self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of glimepiride: development and antidiabetic activity in albino rabbits.
Mohd AB; Sanka K; Bandi S; Diwan PV; Shastri N
Drug Deliv; 2015; 22(4):499-508. PubMed ID: 24471856
[TBL] [Abstract][Full Text] [Related]
10. Strategies to improve dissolution and oral absorption of glimepiride tablets: solid dispersion versus micronization techniques.
Ning X; Sun J; Han X; Wu Y; Yan Z; Han J; He Z
Drug Dev Ind Pharm; 2011 Jun; 37(6):727-36. PubMed ID: 21204747
[TBL] [Abstract][Full Text] [Related]
11. Characterization and therapeutic efficacy evaluation of glimepiride and L-arginine co-amorphous formulation prepared by supercritical antisolvent process: Influence of molar ratio and preparation methods.
Park H; Jin Seo H; Hong SH; Ha ES; Lee S; Kim JS; Baek IH; Kim MS; Hwang SJ
Int J Pharm; 2020 May; 581():119232. PubMed ID: 32240805
[TBL] [Abstract][Full Text] [Related]
12. Implication of inclusion complexation of glimepiride in cyclodextrin-polymer systems on its dissolution, stability and therapeutic efficacy.
Ammar HO; Salama HA; Ghorab M; Mahmoud AA
Int J Pharm; 2006 Aug; 320(1-2):53-7. PubMed ID: 16701974
[TBL] [Abstract][Full Text] [Related]
13. Characterization of tolbutamide polymorphs (Burger's forms II and IV) and polymorphic transition behavior.
Kimura K; Hirayama F; Uekama K
J Pharm Sci; 1999 Apr; 88(4):385-91. PubMed ID: 10187747
[TBL] [Abstract][Full Text] [Related]
14. Surfactant-mediated dissolution of metformin hydrochloride tablets: wetting effects versus ion pairs diffusivity.
Desai D; Wong B; Huang Y; Ye Q; Tang D; Guo H; Huang M; Timmins P
J Pharm Sci; 2014 Mar; 103(3):920-6. PubMed ID: 24549733
[TBL] [Abstract][Full Text] [Related]
15. Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems.
Ammar HO; Salama HA; Ghorab M; Mahmoud AA
Int J Pharm; 2006 Feb; 309(1-2):129-38. PubMed ID: 16377107
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of glimepiride nanocrystal formulation and evaluation of its pharmacokinetic in rats.
Du B; Shen G; Wang D; Pang L; Chen Z; Liu Z
Drug Deliv; 2013; 20(1):25-33. PubMed ID: 23311650
[TBL] [Abstract][Full Text] [Related]
17. New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin.
Taupitz T; Dressman JB; Klein S
Eur J Pharm Biopharm; 2013 May; 84(1):208-18. PubMed ID: 23246797
[TBL] [Abstract][Full Text] [Related]
18. Impact of sodium dodecyl sulphate on the dissolution of poorly soluble drug into biorelevant medium from drug-surfactant discs.
Madelung P; Ostergaard J; Bertelsen P; Jørgensen EV; Jacobsen J; Müllertz A
Int J Pharm; 2014 Jun; 467(1-2):1-8. PubMed ID: 24594297
[TBL] [Abstract][Full Text] [Related]
19. Analysis of chlorthalidone polymorphs in raw materials and tablets and the effect of forms I and II on the dissolution properties of drug products.
Bonfilio R; Leal JS; Santos OM; Pereira GR; Doriguetto AC; de Araújo MB
J Pharm Biomed Anal; 2014 Jan; 88():562-70. PubMed ID: 24216278
[TBL] [Abstract][Full Text] [Related]
20. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
